Search alternatives:
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 64,901 - 64,920 results of 99,842 for search '(( 5 ((teer decrease) OR (we decrease)) ) OR ( 5 ((a decrease) OR (nn decrease)) ))', query time: 1.69s Refine Results
  1. 64901
    Table_2_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.DOCX

    Table_2_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.DOCX by Beth Szyszka-Mroz (13539646)

    Published 2022
    “…Compared to single cells, palmelloids of C. priscuii showed a decrease in the abundance of light-harvesting complex II (LHCII) proteins with a 2-fold higher Chl a/b ratio. …”
    Save to List
    Saved in:
  2. 64902
    Table_2_Evaluation of the Prevalence and Risk Factors for Undernutrition in Hospitalized Dogs.XLSX

    Table_2_Evaluation of the Prevalence and Risk Factors for Undernutrition in Hospitalized Dogs.XLSX by Jenifer Molina (5696585)

    Published 2018
    “…Anorexia at admission (P < 0.001; OR 5.67, 95% CI: 2.23 to 15.47) was associated with a higher risk of death. …”
    Save to List
    Saved in:
  3. 64903
    Table_1_Evaluation of the Prevalence and Risk Factors for Undernutrition in Hospitalized Dogs.DOCX

    Table_1_Evaluation of the Prevalence and Risk Factors for Undernutrition in Hospitalized Dogs.DOCX by Jenifer Molina (5696585)

    Published 2018
    “…Anorexia at admission (P < 0.001; OR 5.67, 95% CI: 2.23 to 15.47) was associated with a higher risk of death. …”
    Save to List
    Saved in:
  4. 64904
    Image_1_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIF

    Image_1_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIF by Beth Szyszka-Mroz (13539646)

    Published 2022
    “…Compared to single cells, palmelloids of C. priscuii showed a decrease in the abundance of light-harvesting complex II (LHCII) proteins with a 2-fold higher Chl a/b ratio. …”
    Save to List
    Saved in:
  5. 64905
    Image_2_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIFF

    Image_2_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIFF by Beth Szyszka-Mroz (13539646)

    Published 2022
    “…Compared to single cells, palmelloids of C. priscuii showed a decrease in the abundance of light-harvesting complex II (LHCII) proteins with a 2-fold higher Chl a/b ratio. …”
    Save to List
    Saved in:
  6. 64906
    Table_1_The inflammatory and metabolic status of patients with sudden-onset sensorineural hearing loss.DOCX

    Table_1_The inflammatory and metabolic status of patients with sudden-onset sensorineural hearing loss.DOCX by Jônatas Bussador do Amaral (13789027)

    Published 2024
    “…/mL). Adiponectin showed a decrease from 553.7 ng/mL in V1 to 454.4 ng/mL in V3.…”
    Save to List
    Saved in:
  7. 64907
    Image_3_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIF

    Image_3_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIF by Beth Szyszka-Mroz (13539646)

    Published 2022
    “…Compared to single cells, palmelloids of C. priscuii showed a decrease in the abundance of light-harvesting complex II (LHCII) proteins with a 2-fold higher Chl a/b ratio. …”
    Save to List
    Saved in:
  8. 64908
    Image_4_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIF

    Image_4_Palmelloid formation in the Antarctic psychrophile, Chlamydomonas priscuii, is photoprotective.TIF by Beth Szyszka-Mroz (13539646)

    Published 2022
    “…Compared to single cells, palmelloids of C. priscuii showed a decrease in the abundance of light-harvesting complex II (LHCII) proteins with a 2-fold higher Chl a/b ratio. …”
    Save to List
    Saved in:
  9. 64909
    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  10. 64910
    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  11. 64911
    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  12. 64912
    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  13. 64913
    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  14. 64914
    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  15. 64915
    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  16. 64916
    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  17. 64917
    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  18. 64918
    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  19. 64919
    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  20. 64920
    Alterations in neural proliferation caused by LOF and GOF of <i>pros</i>.

    Alterations in neural proliferation caused by LOF and GOF of <i>pros</i>. by Jordi Colonques (222976)

    Published 2011
    “…<p>A–I. Confocal projections taken through the OL of <i>w</i>t, <i>pros<sup>v24</sup></i>, and <i>hsGal4;UAS-pros</i> late third instar larvae from a ventro-anterior orientation showing immunostaining for PROS, BrdU and PH3, as indicated. …”
    Save to List
    Saved in:

Search Tools: